Drug Trial Radar · NCT06307652
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4,005
Actual
Start
Apr 12, 2024
Primary completion
Apr 16, 2027
Study completion Apr 16, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Conditions
- Heart Failure and Impaired Kidney Function
Interventions
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mgDrug
1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mgDrug
1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinDrug
1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of any of the components of the composite of: •CV death •HF hospitalisation •HF event without hospitalisationTime frame: Approximately 36 months
Locations
676 sites in 39 countries. Site status is shown where the registry gives one.
Research Site
Alexander City, Alabama
Research Site
Fairhope, Alabama
Research Site
Huntsville, Alabama
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Little Rock, Arkansas
Research Site
Beverly Hills, California
Research Site
Covina, California
Research Site
Encinitas, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Redding, California
Research Site
San Diego, California
Research Site
San Francisco, California
Research Site
San Francisco, California
Research Site
Thousand Oaks, California
Research Site
Vista, California
Research Site
West Hills, California
Research Site
Aurora, Colorado
Research Site
Wheat Ridge, Colorado
Research Site
Altamonte Springs, Florida
Research Site
Boca Raton, Florida
Research Site
Bradenton, Florida
Research Site
Delray Beach, Florida
Research Site
Gainesville, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami Lakes, Florida
Research Site
Safety Harbor, Florida
Research Site
Saint Augustine, Florida
Research Site
St. Petersburg, Florida
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Peachtree City, Georgia
Research Site
Tucker, Georgia
Research Site
Chicago, Illinois
Research Site
Hazel Crest, Illinois
Research Site
North Chicago, Illinois
Showing 40 of 676 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.